方盛制药(603998.SH)拟转让佰骏医疗部份股权 引入战投德维特公司
方盛制药(603998.SH)公布,拟将控股子公司佰骏医疗31.7%股权转让给德维特公司,转让对价1.47亿元人民币(下同);拟将佰骏医疗5.1%股权转让予佰骏医疗员工持股平台;佰骏医疗在长沙新设立的全资子公司,向德维特申请4.5亿元的可以根据转换协议条款转换股份的借款。
股权转让後,公司持有佰骏医疗的股权将减少至14.2%。德维特为肾科领域保健服务提供商DaVitaInc.的间接控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.